Skip to main content
. 2019 Apr 3;33(3):285–297. doi: 10.1007/s40259-019-00345-6

Table 3.

Identified drivers and enablers in the Swedish healthcare system to leverage competition from biosimilars

Drivers Enablers
Quantitative study Qualitative study
The difference in discounted price per DDD between the biosimilar and the originator product (potential savings)

The difference in discounted price per DDD

Key opinion leaders

Local guidelines

Gainsharing

A multi-stakeholder approach

An altruistic attitude

Good communication with colleagues

DDD defined daily dose